A post-hoc analysis from the ReFlaP study showed that there was a significant correlation between PsAID12 & HAQ scores MDA-PsAIDrem (SN 82.6% SP97.1%) and MDA-PsAIDlow (SN 90.7% SP 91.2%) Potential alternative for HAQ in MDA criteria? #ACR25 @RheumNow Abs1411 https://t.co/QAxKsuhtDq

• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1
• https://x.com/RHEUMarampa/status/1982832157505589530/photo/1

In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1022 patient-years. Annual incidence dropped from 2.7 to 0.49 per 100 patient-years. Data from the real world SERENA study. Abstract 1463 @RheumNow #ACR25

In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising. @EBRheum asked what I knew/hoped he’d ask: why did this happen? PJP is v rare in GCA (https://t.co/oPN0dpvG8Q) & with MTX in other diseases. Worth interrogation! #ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR

• https://www.sciencedirect.com/science/article/abs/pii/S0049017222002050
• https://x.com/drdavidliew/status/1982831653023256722/photo/1

POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD MDA 12% vs 22% All elements of MDA response sig different except for Leeds enthesitis index DAPSA Remission 2% vs. 9% PsARC 42% vs. 61% PASDAS -1 vs. -1.7 mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp

• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1
• https://x.com/AurelieRheumo/status/1982831486026826168/photo/1

Many GLP-1 drugs in the pipeline for management in #OA #ACR25 @rheumnow https://t.co/y3UCp0CcUb

• https://x.com/bella_mehta/status/1982831363565731941/photo/1

Semaglitide did help in weight loss and decrease in pain in knee OA https://t.co/240sR5An3m #acr25 @rheumnow Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5

• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis | NEJM
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1
• https://x.com/bella_mehta/status/1982830500915089558/photo/1

GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj

• https://x.com/Dr_Brian_MD/status/1982830407365341680/photo/1

Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1

In pooled PsA trials (n=1222), deucravacitinib reduced disease activity–linked proteomic scores in both sexes by Week 16. Proteomic profiling identified 133 unique proteins in males and 177 in females vs sex-matched healthy controls. Females showed greater enrichment in https://t.co/TTAWUtOLP0

• https://x.com/synovialjoints/status/1982829640927551627/photo/1

#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH

• https://x.com/Yuz6Yusof/status/1982829570597535882/photo/1
• https://x.com/Yuz6Yusof/status/1982829570597535882/photo/1

Abstract 0874: At wk16, deucravacitinib (vs placebo) showed greater efficacy in multiple #PsA disease activity measures 🔹 ↑ MDA, DAPSA LDA/remission, and PsARC responses 🔹 Greater ↓in PASDAS and mCPDAI 🔹 Benefits seen in both men and women @RheumNow #ACR25

Sex based differences in PsA proteomics Analyse from POETYK PSA 1 & 2 deucravacitinib RCT Large overlap but female pts specificities, Upregulation of: -JAK STAT pathway -Cytokine interaction Linked with higher disease activity in female groups Yes Correlation, but not https://t.co/VwiVOkxpoB

• https://x.com/AurelieRheumo/status/1982827696372535302/photo/1
• https://x.com/AurelieRheumo/status/1982827696372535302/photo/1

Open-label MTX vs. Toci in GCA in METOGiA Wk 78: 37% w/o relapse in MTX arm 46% w/o relapse in Toci arm MTX was NOT non-inferior to Toci Toci superior in 2ndary endpoints Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C

• https://x.com/Dr_Brian_MD/status/1982827205349789731/photo/1

List of GLP1 agonists approved currently..would they have effects in #OA Session title is should we gave them to everyone? #ACR25 @RheumNow https://t.co/dXwB6Jkg8C

• https://x.com/bella_mehta/status/1982827011166146579/photo/1

HOPE for Pts w #fibromyalgia #FM #Transcutaneous #electrical #nerve #stimulation + #physio Is Better than #PT alone #Pragmatic #cluster #randomized #trial Answered impt question Does #TENS help Pts w #fibro Too ba noTENS sham Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN

• https://x.com/Janetbirdope/status/1982825297306439912/photo/1